<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02438371</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-15-0134</org_study_id>
    <nct_id>NCT02438371</nct_id>
  </id_info>
  <brief_title>Nifedipine or Nifedipine Plus Indomethacin for Treatment of Acute Preterm Labor</brief_title>
  <official_title>Nifedipine Alone or Nifedipine Plus Indomethacin for Treatment of Acute Preterm Labor: An Open Label, Randomized Comparative Effectiveness Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tocolytic agents are used for the treatment of preterm labor. It is unclear whether
      combination treatments of two tocolytic agents are more effective in stopping preterm labor
      compared to one. Therefore, the investigators propose a comparative effective trial of
      nifedipine plus indomethacin vs. nifedipine alone for the treatment of preterm labor
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators current treatment for preterm labor has not been shown to be effective in
      prolonging pregnancy sufficiently to improve neonatal outcomes and other treatment strategies
      are needed. Multiple examples demonstrate that multi-agent treatments are routine clinical
      practice in other fields of medicine including chemotherapeutics for cancer,
      multi-therapeutics for myocardial infarction and broad spectrum antibiotics for pneumonia. At
      this time, it is unclear if a combination of tocolytic medications for preterm labor is more
      advantageous for women. If pregnancy is prolonged with combined tocolytic therapy, this could
      directly influence the treatment of preterm labor and potentially improve neonatal outcomes.
      There currently are no trials of combination regimens using widely used tocolytic agents,
      such as nifedipine and indomethacin. Thus, we propose a comparative effective trial of
      nifedipine plus indomethacin vs. nifedipine alone for the treatment of preterm labor
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of women who remain pregnant</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of pregnancy</measure>
    <time_frame>up to 9 months</time_frame>
    <description>Length of time from tocolytic initiation to the time of delivery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Preterm Labor</condition>
  <arm_group>
    <arm_group_label>Single</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>They will receive nifedipine for the treatment of preterm labor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>They will receive nifedipine plus indomethacin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine</intervention_name>
    <description>Nifedipine will be given for the treatment of preterm labor</description>
    <arm_group_label>Single</arm_group_label>
    <arm_group_label>Combination</arm_group_label>
    <other_name>Procardia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>Nifedipine and indomethacin will be give for the treatment of pretermlabor</description>
    <arm_group_label>Combination</arm_group_label>
    <other_name>Indomethacin and Nifedipine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  We will include pregnant women between 220/7 to 316/7 weeks gestation who present with
             regular uterine contractions defined as at least one contraction every 10 minutes for
             30 minutes with at least one of the following:

          -  cervical change or

          -  2 cm dilated or

          -  positive fetal fibronectin or

          -  transvaginal cervical length &lt;2.5 cm

        Exclusion Criteria:

          -  We will exclude pregnant women with any contraindication to tocolysis:

          -  clinical chorioamnionitis (defined as a temperature of &gt;100.4 F and any of the
             following: fundal tenderness, maternal tachycardia, fetal tachycardia or purulent
             vaginal discharge)

          -  non reassuring fetal heart tones

          -  suspected placental abruption

          -  preterm premature rupture of membranes

          -  prior tocolytic treatment during their pregnancy

          -  known adverse effect to indomethacin or nifedipine
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Hutchinson, M.S.</last_name>
    <role>Study Director</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jerrie Refuerzo, M.D.</last_name>
    <phone>713-500-6416</phone>
    <email>jerrie.s.refuerzo@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nana Ankumah, M.D.</last_name>
    <phone>713-500-6421</phone>
    <email>nana.ama.e.ankumah@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Hermann Hospital Texas Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerrie S Refuerzo, M.D.</last_name>
      <phone>713-500-6416</phone>
      <email>Jerrie.S.Refuerzo@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maria Hutchinson, M.S</last_name>
      <phone>713-500-5850</phone>
      <email>Maria.S.Keefer@uth.tmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jerrie S Refuerzo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2015</study_first_submitted>
  <study_first_submitted_qc>May 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Jerrie Refuerzo</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>pregnancy</keyword>
  <keyword>preterm labor</keyword>
  <keyword>tocolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nifedipine</mesh_term>
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

